Suarez S, O'Hara P, Kazantseva M, Newcomer C E, Hopfer R, McMurray D N, Hickey A J
School of Pharmacy, and Department of Pathology and Laboratory Animal Medicine, University of North Carolina at Chapel Hill, 27599, USA.
J Antimicrob Chemother. 2001 Sep;48(3):431-4. doi: 10.1093/jac/48.3.431.
A Mycobacterium tuberculosis (H37Rv)-infected guinea pig model was used to screen for targeted delivery to the lungs by insufflation (with lactose excipient) or nebulization, of either rifampicin alone, rifampicin within poly(lactide-co-glycolide) microspheres (R-PLGA) or polymer microparticles alone (PLGA). Animals treated with single and double doses of R-PLGA microspheres exhibited significantly reduced numbers of viable bacteria, inflammation and lung damage compared with lactose-, PLGA- or rifampicin-treated animals 28 days post-infection (P < 0.05). Two doses of R-PLGA resulted in reduced splenic enlargement. These studies support the potential of R-PLGA delivered to the lung to treat pulmonary tuberculosis.
使用结核分枝杆菌（H37Rv）感染的豚鼠模型，通过吹入（使用乳糖辅料）或雾化，筛选单独的利福平、聚（丙交酯-共-乙交酯）微球（R-PLGA）中的利福平或单独的聚合物微粒（PLGA）向肺部的靶向递送。与感染后28天接受乳糖、PLGA或利福平治疗的动物相比，接受单剂量和双剂量R-PLGA微球治疗的动物体内活菌数量、炎症和肺损伤显著减少（P<0.05）。两剂R-PLGA可减轻脾脏肿大。这些研究支持了将R-PLGA递送至肺部治疗肺结核的潜力。
